Didrex (benzphetamine) / Pfizer - LARVOL DELTA

A flexible linker of 8-amino acids between the membrane binding segment and the FMN domain of cytochrome P450 reductase is necessary for optimal activity. (PubMed, J Inorg Biochem) - "Although electron transfer to forty-eight human CYP enzymes by the FMN hydroquinone of CYPOR is well-known, the role of the linker between the NH2-terminus membrane-binding domain (MBD) and FMN domain in supporting the activity of P450 enzymes remains poorly understood...Dr. Rwere appreciate his contributions to the development of talented Black scientists from Africa."

Journal • MB

Weight loss medication prescription prevalence in the active component, 2018-2023. (PubMed, MSMR) - "The findings indicate a significant rise in the period prevalence of weight loss prescriptions over time. Further research is recommended to assess the effectiveness, safety, and use in austere military environments."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Comparison table: Some FDA-approved drugs for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

FDA event • Journal

Drugs and devices for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Amphipol-facilitated Elucidation of the Functional Tetrameric Complex of Full-length Cytochrome P450 CYP2B4 and NADPH-Cytochrome-P450 Oxidoreductase. (PubMed, J Biol Chem) - "Incorporation of CYP2B4 and POR into APols resulted in a CYP2B4:POR complex with a stoichiometry of 1:1, which was fully functional in demethylating benzphetamine at a turnover rate of 37.7±2.2 min, with a coupling efficiency of 40%...Moreover, negative stain electron microscopy (EM) validated the homogeneity of the complex, and allowed us to generate a three-dimensional EM map and model consistent with the tetramer observed in solution. This first report of the full-length mammalian CYP:POR complex by transmission EM not only reveals the architecture that facilitates electron transfer, but also highlights a potential use of APols in biochemical and structural studies of functional CYP complexes with redox partners."

Journal

TRENDS OF SLEEVE GASTRECTOMY AND POST-OPERATIVE WEIGHT LOSS PHARMACOTHERAPY OVER 10 YEARS: A LARGE DATABASE STUDY (SSAT 2020) - "We studied the individuals who were prescribed at least one weight loss medication [orlistat, liraglutide (Saxenda), lorcaserin, phentermine-topiramate, bupropion-naltrexone, phentermine, diethylpropion, benzphetamine, and phendimetrazine] at least 7 days after the procedure...Despite the growing trend, sleeve gastrectomy and post-operative anti-obesity pharmacotherapy are underutilized in the US with < 1% of obese adults undergoing SG out of which < 5% being prescribed anti-obesity pharmacotherapy. Further large-scale studies are required to explore interventions to increase the utilization of these therapies."

Genetic Disorders • Obesity

PHARMACOTHERAPY FOR OBESITY – TRENDS USING A POPULATION LEVEL NATIONAL DATABASE (DDW 2020) - "Long-term (> 12 weeks), FDA approved agents include orlistat, liraglutide (Saxenda), lorcaserin, phentermine-topiramate, bupropion-naltrexone. Short-term agents ( 5 years ago, only a small fraction of obese adults have been prescribed these drugs. Further studies are required to explore the barriers involved in the prescription of these medications and other reasons for their slow implementation."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Psychiatry

TRENDS OF SLEEVE GASTRECTOMY AND POST-OPERATIVE WEIGHT LOSS PHARMACOTHERAPY OVER 10 YEARS: A LARGE DATABASE STUDY (DDW 2020) - "We studied the individuals who were prescribed at least one weight loss medication [orlistat, liraglutide (Saxenda), lorcaserin, phentermine-topiramate, bupropion-naltrexone, phentermine, diethylpropion, benzphetamine, and phendimetrazine] at least 7 days after the procedure...Despite the growing trend, sleeve gastrectomy and post-operative anti-obesity pharmacotherapy are underutilized in the US with < 1% of obese adults undergoing SG out of which < 5% being prescribed anti-obesity pharmacotherapy. Further large-scale studies are required to explore interventions to increase the utilization of these therapies."

Genetic Disorders • Metabolic Disorders • Obesity